semaglutide and gallstones Are (cholelithiasis) a contraindication to therapy? GLP-1 receptor agonists and gallbladder

Food Sci Biotechnol 27:193202

There was a significant 24% reduction in the composite primary outcome in the semaglutide group compared with those taking placebo, with first events occurring in 5.8 versus 7.5 people per 100 person-years of follow-up, such that 20 people would need to be treated for 3 years to prevent one primary event

Thus, on a product-level fundamentals, this could be the early phase of an inflection rather than a one-off pop

Its current list of substances with possible safety risks includes peptides that the agency believes may expose patients to serious harm

Eli Lilly and Novartis (speakers bureau

Over-the-counter pain relievers can help manage any discomfort